In melanoma, phenotype plasticity is a major cause for therapeutic resistance and is associated with increased levels of epidermal growth factor receptor (EGFR), receptor tyrosine kinaseAXL, or nerve growth factor receptor (NGFR), the expression of which is further upregulated by v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors (44). Here, NGFR is linked to melanoma.